Tasly Pharmaceutical Group Co., Ltd
Shanghai Stock ExchangeTotal Valuation
Tasly Pharmaceutical Group Co., Ltd carries a market capitalization of 21.56B, placing it among publicly traded companies globally. Its enterprise value stands at 21.07B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 21.56B |
| Enterprise Value | 21.07B |
Share Statistics
Tasly Pharmaceutical Group Co., Ltd currently has 1.49B shares outstanding.
| Shares Outstanding | 1.49B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Tasly Pharmaceutical Group Co., Ltd trades at a trailing price-to-earnings ratio of 21.89. The price-to-sales ratio is 2.78, and the price-to-book ratio stands at 2.31.
| PE Ratio | 21.89 |
| PS Ratio | 2.78 |
| PB Ratio | 2.31 |
| P/TBV Ratio | 2.22 |
| P/FCF Ratio | 37.71 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Tasly Pharmaceutical Group Co., Ltd trades at an EV/EBITDA multiple of 14.96 and an EV/FCF ratio of 32.61. The EV/Sales ratio of 2.50 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 14.96 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.50 |
| EV / EBITDA | 14.96 |
| EV / EBIT | 14.96 |
| EV / FCF | 32.61 |
Financial Position
Tasly Pharmaceutical Group Co., Ltd maintains a current ratio of 3.31, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.43, indicating elevated leverage, while an interest coverage ratio of 45.45 demonstrates strong ability to service its debt obligations.
| Current Ratio | 3.31 |
| Quick Ratio | 1.71 |
| Debt / Equity | 13.43 |
| Debt / EBITDA | 1.20 |
| Interest Coverage | 45.45 |
Financial Efficiency
Tasly Pharmaceutical Group Co., Ltd posts a return on equity of 10.64 and a return on invested capital of 7.94.
| Return on Equity (ROE) | 10.64 |
| Return on Assets (ROA) | 6.46 |
| Return on Invested Capital (ROIC) | 7.94 |
| Return on Capital Employed (ROCE) | 9.36 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.64 |
Taxes
Over the trailing twelve months, Tasly Pharmaceutical Group Co., Ltd has paid 184.94M in income taxes, reflecting an effective tax rate of 15.66.
| Income Tax | 184.94M |
| Effective Tax Rate | 15.66 |
Stock Price Statistics
Tasly Pharmaceutical Group Co., Ltd's stock has declined approximately -9.3593% over the past 52 weeks. The 50-day moving average sits at 14.34, while the 200-day moving average is 14.85.
| Beta (5Y) | N/A |
| 52-Week Price Change | -9.3593% |
| 50-Day Moving Average | 14.34 |
| 200-Day Moving Average | 14.85 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Tasly Pharmaceutical Group Co., Ltd generated 8.41B in revenue and converted that into 1.07B in net income, yielding earnings per share of 0.67. EBITDA reached 1.41B, while operating income came in at 1.41B.
| Revenue | 8.41B |
| Gross Profit | 5.65B |
| Operating Income | 1.41B |
| Pretax Income | 1.18B |
| Net Income | 1.07B |
| EBITDA | 1.41B |
| EBIT | 1.41B |
| Earnings Per Share (EPS) | 0.67 |
Balance Sheet
Tasly Pharmaceutical Group Co., Ltd holds 4.23B in cash and equivalents against 1.69B in total debt, resulting in a net debt position of -1.86B. Total book value stands at 10.12B, with working capital of 5.70B providing operational flexibility.
| Cash & Cash Equivalents | 4.23B |
| Total Debt | 1.69B |
| Net Debt | -1.86B |
| Equity (Book Value) | 10.12B |
| Book Value Per Share | 6.78 |
| Working Capital | 5.70B |
Cash Flow
After subtracting -619.94M in capital expenditures, free cash flow totaled -619.94M - equivalent to -0.41 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -619.94M |
| Free Cash Flow | -619.94M |
| FCF Per Share | -0.41 |
Margins
Tasly Pharmaceutical Group Co., Ltd operates with a gross margin of 67.10, reflecting its pricing power and cost economics. The operating margin of 16.74 and net profit margin of 12.69 provide insight into operational efficiency.
| Gross Margin | 67.10 |
| Operating Margin | 16.74 |
| Pretax Margin | 14.03 |
| Profit Margin | 12.69 |
| EBITDA Margin | 16.74 |
Dividends & Yields
The company's payout ratio of 90.68 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.56 |
| Dividend Yield | N/A |
| Payout Ratio | 90.68 |
| Shareholder Yield | 10.03 |
| FCF Yield | 2.65 |
Stock Splits
Tasly Pharmaceutical Group Co., Ltd's most recent stock split took place on June 5, 2018 with a 5:7 split ratio.
| Last Split Date | 6/5/2018 |
| Split Ratio | 5:7 |
Scores
Tasly Pharmaceutical Group Co., Ltd posts an Altman Z-Score of 7.32, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.32 |